Suppression of type 1 pilus assembly in uropathogenic Escherichia coli by chemical inhibition of subunit polymerization

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 4, 2014, Pages 1017-1026

  Lo, Alvin W H ^a,b   Van de Water, Karen ^a,b   Gane, Paul J ^c   Chan, A W Edith ^c   Steadman, David ^c,d   Stevens, Kiri ^c,d   Selwood, David L ^c   Waksman, Gabriel ^d,e   Remaut, Han ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anti virulence; Chaperone usher pathway; Type 1 pili; UPEC; Urinary tract infections

Indexed keywords

CHAPERONE;

ARTICLE; BACTERIUM ADHERENCE; BACTERIUM CULTURE; BIOFILM; BIOGENESIS; BLADDER; CELL GROWTH; COMPUTER MODEL; EPITHELIUM CELL; IN VITRO STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERIZATION; UROPATHOGENIC ESCHERICHIA COLI;

ANTI-VIRULENCE; CHAPERONE-USHER PATHWAY; TYPE 1 PILI; UPEC; URINARY TRACT INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BIOFILMS; CELL LINE; EPITHELIAL CELLS; FIMBRIAE, BACTERIAL; HUMANS; MACROMOLECULAR SUBSTANCES; PROTEIN MULTIMERIZATION; PROTEIN SUBUNITS; UROPATHOGENIC ESCHERICHIA COLI;

EID: 84896473267     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt467     Document Type: Article

References (56)

1. Fronzes R, Remaut H, Waksman G. Architectures and biogenesis of non-flagellar protein appendages in Gram-negative bacteria. EMBO J 2008; 27: 2271-80.
2. Cameron TA, Zambryski PC. Disarming bacterial type IV secretion. Chem Biol 2012; 19: 934-6.
3. Duncan MC, Linington RG, Auerbuch V. Chemical inhibitors of the type three secretion system: disarming bacterial pathogens. Antimicrob Agents Chemother 2012; 56: 5433-41.
4. Lo AW, Moonens K, Remaut H. Chemical attenuation of pilus function and assembly in Gram-negative bacteria. Curr Opin Microbiol 2013; 16: 85-92.
5. Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis 2001; 183 Suppl 1: S1-4.
6. Blango MG, Mulvey MA. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 2010; 54: 1855-63.
7. Qi C, Pilla V, Yu JH et al. Changing prevalence of Escherichia coli with CTX-M-type extended-spectrum β-Lactamases in outpatient urinary E. coli between 2003 and 2008. Diagn Microbiol Infect Dis 2010; 67: 87-91.
8. Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother 2011; 66: 1-14.
9. Totsika M, Kostakioti M, Hannan TJ et al. A FimH inhibitor prevents acute bladder infection and treats chronic cystitis caused by multidrug-resistant uropathogenic Escherichia coli ST131. J Infect Dis 2013; 208: 921-8.
10. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002; 113 Suppl 1A: 5S-13S.
11. Connell I, Agace W, Klemm P et al. Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci USA 1996; 93: 9827-32.
12. Justice SS, Hunstad DA, Seed PC et al. Filamentation by Escherichia coli subverts innate defenses during urinary tract infection. Proc Natl Acad Sci USA 2006; 103: 19884-9.
13. Wright KJ, Seed PC, Hultgren SJ. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell Microbiol 2007; 9: 2230-41.
14. Cegelski L, Marshall GR, Eldridge GR et al. The biology and future prospects of antivirulence therapies. Nat Rev Microbiol 2008; 6: 17-27.
15. Waksman G, Hultgren SJ. Structural biology of the chaperone-usher pathway of pilus biogenesis. Nat Rev Microbiol 2009; 7: 765-74.
16. Nuccio SP, Baumler AJ. Evolution of the chaperone/usher assembly pathway: fimbrial classification goes Greek. Microbiol Mol Biol Rev 2007; 71: 551-75.
17. Allen WJ, Phan G, Waksman G. Pilus biogenesis at the outer membrane of Gram-negative bacterial pathogens. Curr Opin Struct Biol 2012; 22: 500-6.
18. Geibel S, Procko E, Hultgren SJ et al. Structural and energetic basis of folded-protein transport by the FimD usher. Nature 2013; 496: 243-6.
19. Phan G, Remaut H, Wang T et al. Crystal structure of the FimD usher bound to its cognate FimC-FimH substrate. Nature 2011; 474: 49-53.
20. Choudhury D, Thompson A, Stojanoff V et al. X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli. Science 1999; 285: 1061-6.
21. Sauer FG, Futterer K, Pinkner JS et al. Structural basis of chaperone function and pilus biogenesis. Science 1999; 285: 1058-61.
22. Sauer FG, Pinkner JS, Waksman G et al. Chaperone priming of pilus subunits facilitates a topological transition that drives fiber formation. Cell 2002; 111: 543-51.
23. Remaut H, Rose RJ, Hannan TJ et al. Donor-strand exchange in chaperone-assisted pilus assembly proceeds through a concerted b strand displacement mechanism. Mol Cell 2006; 22: 831-42.
24. Nishiyama M, Ishikawa T, Rechsteiner H et al. Reconstitution of pilus assembly reveals a bacterial outer membrane catalyst. Science 2008; 320: 376-9.
25. Saulino ET, Bullitt E, Hultgren SJ. Snapshots of usher-mediated protein secretion and ordered pilus assembly. Proc Natl Acad Sci USA 2000; 97: 9240-5.
26. Saulino ET, Thanassi DG, Pinkner JS et al. Ramifications of kinetic partitioning on usher-mediated pilus biogenesis. EMBO J 1998; 17: 2177-85.
27. Scholz O, Thiel A, HillenWet al. Quantitative analysis of gene expression with an improved green fluorescent protein. p6. Eur J Biochem 2000; 267: 1565-70.
28. Irwin JJ, Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005; 45: 177-82.
29. Lipinski CA, Lombardo F, Dominy BW et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
30. Molecular Operating Environment (MOE). Montreal, Canada: Chemical Computing Group Inc., 2011.
31. McGann M. FRED and HYBRID docking performance on standardized datasets. J Comput Aided Mol Des 2012; 26: 897-906.
32. Eldridge MD, Murray CW, Auton TR et al. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 1997; 11: 425-45.
33. Jones G, Willett P, Glen RCet al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267: 727-48.
34. Willett JP, Glen RC, Leach AR et al. Further development of a genetic algorithm for ligand docking and its application to screening combinatorial libraries. In: Parrill AL, Reddy MR, eds. Rational Drug Design: Novel Methodology and Practical Applications. Washington, DC: American Chemical Society, 1999; 271-91.
35. O'Toole GA, Kolter R. Initiation of biofilm formation in Pseudomonas fluorescens WCS365 proceeds via multiple, convergent signalling pathways: a genetic analysis. Mol Microbiol 1998; 28: 449-61.
36. Kostakioti M, Hadjifrangiskou M, Cusumano CK et al. Distinguishing the contribution of type 1 pili from that of other QseB-misregulated factors when QseC is absent during urinary tract infection. Infect Immun 2012; 80: 2826-34.
37. Wellens A, Garofalo C, Nguyen H et al. Intervening with urinary tract infections using anti-adhesives based on the crystal structure of the FimH-oligomannose-3 complex. PLoS One 2008; 3: e2040.
38. Brinton CC Jr. The structure, function, synthesis and genetic control of bacterial pili and a molecular model for DNA and RNA transport in gram negative bacteria. Trans N Y Acad Sci 1965; 27: 1003-54.
39. Nishiyama M, Horst R, Eidam O et al. Structural basis of chaperonesubunit complex recognition by the type 1 pilus assembly platform FimD. EMBO J 2005; 24: 2075-86.
40. Anderson GG, Palermo JJ, Schilling JD et al. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 2003; 301: 105-7.
41. Pratt LA, Kolter R. Genetic analysis of Escherichia coli biofilm formation: roles of flagella, motility, chemotaxis and type I pili. Mol Microbiol 1998; 30: 285-93.
42. Jacob-Dubuisson F, Striker R, Hultgren SJ. Chaperone-assisted self-assembly of pili independent of cellular energy. J Biol Chem 1994; 269: 12447-55.
43. Ronald LS, Yakovenko O, Yazvenko N et al. Adaptive mutations in the signal peptide of the type 1 fimbrial adhesin of uropathogenic Escherichia coli. Proc Natl Acad Sci USA 2008; 105: 10937-42.
44. Mulvey MA, Lopez-Boado YS, Wilson CL et al. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 1998; 282: 1494-7.
45. Dethlefsen L,HuseS, SoginMLet al. The pervasive effects ofanantibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol 2008; 6: e280.
46. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial therapy. Nat Chem Biol 2007; 3: 541-8.
47. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 2010; 9: 117-28.
48. Bouckaert J, Berglund J, Schembri M et al. Receptor binding studies disclose a novel class of high-affinity inhibitors of the Escherichia coli FimH adhesin. Mol Microbiol 2005; 55: 441-55.
49. Klein T, Abgottspon D, Wittwer M et al. FimH antagonists for the oral treatment of urinary tract infections: from design and synthesis to in vitro and in vivo evaluation. J Med Chem 2010; 53: 8627-41.
50. Schwardt O, Rabbani S, Hartmann M et al. Design, synthesis and biological evaluation of mannosyl triazoles as FimH antagonists. Bioorg Med Chem 2011; 19: 6454-73.
51. Cusumano CK, Pinkner JS, Han Z et al. Treatment and prevention of urinary tract infection with orally active FimH inhibitors. Sci Transl Med 2011; 3: 109ra115.
52. Jiang X, Abgottspon D, Kleeb S et al. Antiadhesion therapy for urinary tract infections-a balanced PK/PD profile proved to be key for success. J Med Chem 2012; 55: 4700-13.
53. Svensson A, Larsson A, Emtenas H et al. Design and evaluation of pilicides: potential novel antibacterial agents directed against uropathogenic Escherichia coli. Chembiochem 2001; 2: 915-8.
54. De Greve H, Wyns L, Bouckaert J. Combining sites of bacterial fimbriae. Curr Opin Struct Biol 2007; 17: 506-12.
55. Zav'yalov V, Zavialov A, Zav'yalova G et al. Adhesive organelles of Gram-negative pathogens assembled with the classical chaperone/usher machinery: structure and function from a clinical standpoint. FEMS Microbiol Rev 2010; 34: 317-78.
56. Moonens K, Bouckaert J, Coddens A et al. Structural insight in histo-blood group binding by the F18 fimbrial adhesin FedF. Mol Microbiol 2012; 86: 82-95.